SEVERE APLASTIC ANEMIA
Clinical trials for SEVERE APLASTIC ANEMIA explained in plain language.
Never miss a new study
Get alerted when new SEVERE APLASTIC ANEMIA trials appear
Sign up with your email to follow new studies for SEVERE APLASTIC ANEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New stem cell infusion could boost transplant success in rare blood disorder
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests whether adding specially grown umbilical cord stem cells to a standard bone marrow transplant can improve outcomes for people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. About 40 participants ag…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare bone marrow diseases: drug tames immune attack
Disease control OngoingThis study tests a pill called ruxolitinib for people whose immune system attacks their bone marrow, causing conditions like severe anemia. The drug aims to stop this attack and help the bone marrow recover. Participants take the pill twice daily for up to 6 months and are follow…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Bone marrow transplant or drugs? landmark trial for rare blood disease
Disease control OngoingThis phase 3 trial compares two standard treatments for severe aplastic anemia (SAA) in patients up to age 25 who lack a matched sibling donor: unrelated donor bone marrow transplant (URD BMT) versus immune suppressive therapy (IST). The study measures which approach better preve…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: PHASE3 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New transplant method aims to reduce dangerous immune reactions
Disease control OngoingThis study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo shows promise for rare blood disorder
Disease control OngoingThis study tests whether adding eltrombopag to standard immunosuppressive therapy can improve blood cell counts in people with untreated severe aplastic anemia. Participants receive horse-ATG and cyclosporine plus eltrombopag for up to 6 months. The goal is to see if this combina…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug may keep aplastic anemia from returning
Disease control OngoingThis study tests whether the drug sirolimus can prevent severe aplastic anemia from coming back after patients stop taking cyclosporine. About 84 people aged 2 and older who have responded to initial treatment will be randomly assigned to either take sirolimus for 3 months or jus…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New transplant method aims to cut dangerous immune reaction in half-matched donors
Disease control OngoingThis study tests a stem cell transplant method that removes certain immune cells from the donor's blood to lower the chance of graft-versus-host disease (GvHD), a serious complication. It involves 3 patients with blood cancers or non-cancerous blood disorders who lack a perfectly…
Matched conditions: SEVERE APLASTIC ANEMIA
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC